CAJ | 학술논문

目的：评价贝伐单抗联合化疗治疗复发性卵巢癌的临床疗效及安全性。方法回顾性分析我院收治的37例复发性卵巢癌患者的临床资料，所有患者接受至少2个周期的贝伐单抗联合化疗方案（7.5 mg· kg－1贝伐单抗＋0.9％氯化钠250 mL静脉滴注60 min），并在化疗方案开始前1 h输注完毕。按实体肿瘤疗效评价标准（RECIST）和血清糖类癌症抗原125（CA125）标准分析患者的客观有效率，同时分析患者的生存时间及不良反应发生率。结果治疗后，患者的客观有效率为32.4％（ RECIST标准）和43.2％（ CA125标准）、中位无疾病进展生存时间为5.4个月。2例患者达到完全缓解，无疾病进展生存时间分别为10.0个月和11.2个月。血液学不良反应主要为Ⅰ～Ⅱ级中性粒细胞减少和血小板减少。非血液学不良反应主要为Ⅰ～Ⅱ级恶心呕吐，腹泻和高血压。结论贝伐单抗联合化疗治疗复发性卵巢癌的临床疗效确切，可作为复发性卵巢癌的备选治疗方案。
목적：평개패벌단항연합화료치료복발성란소암적림상료효급안전성。방법회고성분석아원수치적37례복발성란소암환자적림상자료，소유환자접수지소2개주기적패벌단항연합화료방안（7.5 mg· kg－1패벌단항＋0.9％록화납250 mL정맥적주60 min），병재화료방안개시전1 h수주완필。안실체종류료효평개표준（RECIST）화혈청당유암증항원125（CA125）표준분석환자적객관유효솔，동시분석환자적생존시간급불량반응발생솔。결과치료후，환자적객관유효솔위32.4％（ RECIST표준）화43.2％（ CA125표준）、중위무질병진전생존시간위5.4개월。2례환자체도완전완해，무질병진전생존시간분별위10.0개월화11.2개월。혈액학불량반응주요위Ⅰ～Ⅱ급중성립세포감소화혈소판감소。비혈액학불량반응주요위Ⅰ～Ⅱ급악심구토，복사화고혈압。결론패벌단항연합화료치료복발성란소암적림상료효학절，가작위복발성란소암적비선치료방안。
Objective To evaluate the clinical efficacy and safety of bevacizumab combined with chemotherapy in the treatment of recurrence ovarian cancer.Methods Thirty seven ovarian cancer patients with complete data who treated with bevacizumab combined with chemotherapy were reviewed from the data bases of our hospital and included in this retrospective study.All included patients received more than 2 cycles of bevacizumab based combination therapy with eligible for the efficacy and toxicity assessments.The objective response rate was recorded and evaluated according to the response evaluation criteria in solid tumors (RECIST) and cancer antigen 125 (CA125) criteria.The data of survival time and adverse drug reactions were analysised . Results After treatment, the objective response rate were 32.4%and 43.2%respective-ly by the RECIST criteria and CA125 criteria.The median progression free survival for the 37 cases was 5.4 months.The two complete response patients had longest DFS interval with one for 10.0 months and another for 11.2 months.The main hematologic toxicity and non-hematologic toxicity were gradeⅠ-Ⅱneutropenia, thrombocytopenia, nausea and vomiting et al.Conclusion With acceptable toxicity and relative well clinical activity, the bevacizumab combined chemotherapy can be a potential treatment modality for the recurrent or platinum-refractory ovarian cancer.